## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
---

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See In:	struction 10.			
1. Name and Addres Basho Chand		erson*	2. Issuer Name <b>and</b> Ticker or Trading Symbol Astrana Health, Inc. [ ASTH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) C/O ASTRANA	(First) HEALTH, IN	(Middle) C.	3. Date of Earliest Transaction (Month/Day/Year) 04/02/2024	X         Officer (give title below)         Other (specify below)           CFO and COO         CFO and COO
1668 S. GARFII (Street)	ELD AVENUE	<u></u>	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
ALHAMBRA (City)	CA (State)	91801 (Zip)	—	
		<b>T</b> 1 1 1 N	Devise the Original Discourse of the Devise	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	04/02/2024		Α		15,692(1)	A	\$ <mark>0</mark>	172,783(2)	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (In	nstr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Num Derivat Securit Acquir or Disp (D) (Ins and 5)	tive ties ed (A) posed of	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and A Securities U Derivative Se (Instr. 3 and	nderlying ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

## Explanation of Responses:

1. Represents a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares shall vest in eight equal semi-annual installments beginning on October 2, 2024 (the six month anniversary of the grant date).

2. Includes 152,372 shares of unvested restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 21,640 shares, which vest in three equal annual installments on April 14, 2024, 2025, and 2025; (ii) 9,121 shares, which vest in two equal annual installments on May 16, 2024 and 2025; (iii) 60,808 shares, which vest in four equal annual installments on May 16, 2024, and 2027; and (iv) 60,803 shares, which vest upon achievement of certain pre-established performance goals. Also includes 15,692 restricted stock units, which will vest in eight equal semi-annual installments beginning on October 2, 2024 (subject to continuous employment with the Issuer).

## Remarks:

Effective February 26, 2024, the Issuer changed its legal name from Apollo Medical Holdings, Inc. to Astrana Health, Inc.

<u>/s/</u>	Chand	lan E	<b>Bas</b>	<u>ho</u>

\*\* Signature of Reporting Person

04/03/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.